嵌合抗原受体
溶瘤病毒
医学
细胞疗法
联合疗法
封锁
免疫疗法
放射治疗
抗原
免疫检查点
T细胞
癌症研究
癌症
免疫系统
靶向治疗
肿瘤科
免疫学
细胞
受体
药理学
内科学
生物
遗传学
作者
Luyao Wang,Ruixue Yao,Lifa Zhang,Cheng Fan,Leina Ma,Jia Liu
标识
DOI:10.1016/j.intimp.2019.01.010
摘要
Chimeric antigen receptor T (CAR-T) cell therapy provides possibility for the treatment of malignancies since clinical trials have shown that CAR-T therapy has a significant anti-tumor effect. Although many efforts have been made to improve the efficacy and reduce the side effects of CAR-T therapy, there are still many problems to solve. With the rapid development of this field, combination immunotherapy has been proved to improve the efficacy of CAR-T therapy. Studies have shown that radiotherapy, chemotherapy, oncolytic virotherapy, BTK inhibitors and immune checkpoint blockade-based therapy may further enhance the efficacy of CAR-T therapy while CRISPR/Cas9 technology and IL-1 blockade may improve the safety. In this review, we summarized the advantages and the mechanisms of the combination immunotherapy based on CAR-T cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI